Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HB0025 in Advanced Solid Tumors
NCT04678908Phase 1Unknown
- Sponsor
- Huabo Biopharm
- Start
- Mar 2021
- Primary completion
- Feb 2024
- Modality
- Bispecific Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of sotiburafusp alfa in solid tumor (advanced stage), hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC) and 2 more, sponsored by Huabo Biopharm. Primary endpoints: Safety assessment in dose-escalation phase at 240 Days and Efficacy assessment in dose-expansion phase up to 24 Months. Status: unknown.
02
Drugs
sotiburafusp alfa
03
Conditions
solid tumor (advanced stage)hepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)endometrial carcinoma
Beyond the preview
Go deeper on NCT04678908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04678908.